Issued: May 2012.
Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence in 2012. Publication and catalogue information, links to buy online and reader comments.